PharmTech

WuXi Biologics Collabs with HanchorBio on Next-Generation Fusion Protein Pipelines

HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, ...

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for ...
News-Medical.Net on MSN

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, ...
The Pharma Letter

WuXi Biologics, Sinorda team up on bispecific antibody for IBD

China-based biologics services group WuXi Biologics (HKG: 2269) has entered a strategic collaboration with Sinorda ...

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and ...
Contract Pharma

WuXi Biologics, Sinorda Biomedicine Partner to Advance SND006

WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006.
The Pharma Letter

HanchorBio taps WuXi to industrialize fusion-protein pipeline

Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop ...
Seeking Alpha

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing

SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has ...
Seeking Alpha

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic ...
News Medical on MSN

WuXi Biologics and Hanchorbio enter strategic partnership to advance next-generation bi- and multi-functional fusion protein pipeline

WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation ...
Pharmabiz

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...